Tech Company Financing Transactions
Leuko Funding Round
Good Growth Capital, HTH VC and IAG Capital Partners participated in a $5 million Series A funding round for Leuko. This venture round was announced on 9/23/2022.
Transaction Overview
Company Name
Announced On
9/23/2022
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to accelerate clinical trials to obtain regulatory approval in collaboration with cancer centers, including Boston Medical Center and MD Anderson in the USA, and Dexeus and Hospital 12 de Octubre in Europe, and continue to pursue its go-to-market and partnership activities with healthcare providers, medical device distributors and pharmaceutical companies.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
8 St. Mary's St. 613
Boston, MA 02215
USA
Boston, MA 02215
USA
Phone
Undisclosed
Website
Email Address
Overview
Improving quality of life and outcomes for chemotherapy patients and others at risk of severe neutropenia, through the first noninvasive white cell monitor. This is an investigational device. It is not for sale. The claims made on this website have not been evaluated by the FDA or the CE Mark authorities.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carlos Gonzalez
Chief Medical Officer
Alvaro Sanchez-Ferro
Chief Technical Officer
Ian Butterworth
Browse more venture capital transactions:
Prev: 9/23/2022: 3Commas venture capital transaction
Next: 9/23/2022: Nibiru venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs